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The thyroid is an endocrine gland, located ventrally from the trachea. The gland 
consists of two lobes that are connected through the isthmus. The thyroid is composed 
of follicles, follicular cells, and parafollicular cells (also called C cells) (1). The follicular 
cells produce thyroxin (T4, thyroid hormone) and triiodothyronine (T3), which are 
composed of iodine and thyroglobulin (Tg, a precursor protein from the thyroid). T4 
is the sole product of the thyroid gland, whereas T3 is produced in the thyroid and 
peripheral organs by deiodination of T4. Thyroid hormones are involved in a wide range 
of mechanisms within the body, and affect basal metabolic activity, growth, and neural 
development (2). Calcitonin, a hormone produced by the C cells and this hormone 
decreases the blood calcium concentration (3). The hypothalamic-pituitary-thyroid 
axis regulates the synthesis of the thyroid hormones. The hypothalamus releases 
thyrotropin-releasing hormone (TRH), causing the anterior pituitary gland to secrete 
thyroid-stimulating hormone (TSH). This results in thyroid hormone synthesis and 
secretion. T3 and T4 subsequently provide negative feedback to the hypothalamus 
and the pituitary gland (2).
Thyroid cancer and differentiated thyroid cancer
Thyroid cancer ensues when cells of the thyroid gland reproduce uncontrollably 
and develop the potential to spread (metastasize). Histologically, the most common 
subtype of thyroid cancer is (well-)differentiated thyroid cancer (DTC, which includes 
papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC)). DTC accounts for 
90% of all thyroid cancers (4, 5). Differentiated cancers derive from the follicular cells. 
DTC can occur at all ages, but its peak incidence is from the 3rd to 5th life decades (4). 
Poorly differentiated thyroid cancers, such as medullary thyroid cancer (MTC, arising 
from C cells) and anaplastic thyroid cancer (ATC, arising from the follicular epithelium) 
are less common (5, 6).
Differentiated thyroid cancer in children
DTC in children (diagnosed before the age of 19 years) is rare, but incidence rates 
are increasing (7). Age-adjusted incidence rates of childhood DTC are 0.6 to 11.0 
per 100,000, varying between age group and country of origin (7-9). Most children 
diagnosed with DTC are post-pubertal. Up to puberty, the incidence of DTC in boys and 
girls is similar, but from puberty onwards most patients are female (6), making female 
sex the most important risk factor for DTC. The explanation for this sex-dependent 
diagnosis probably lies within the proliferative effect of estrogen on thyroid cells, but 
the exact mechanism is not completely understood (10-12). The emergence of thyroid 
cancer cannot always be explained, but known risk factors for developing childhood 
thyroid cancer are exposure to radiation, iodine deficiency, a positive family history 




Symptoms of childhood differentiated thyroid cancer
Children most often present with an asymptomatic solitary thyroid nodule or 
neck mass. Compressive symptoms, such as hoarseness, dysphagia, dyspnea, or 
experiencing a choking sensation are less common (16-18).
Diagnosis and treatment of childhood differentiated thyroid cancer
Up to now, three official guidelines for the management of DTC in children have been 
published (19-21). Clinical evaluation, ultrasonography (US), and fine needle aspiration 
(FNA) are used to determine the origin of the thyroid nodule or neck mass (19). FNA 
can be makes it possible to obtain cells of the thyroid nodule and/or suspicious lymph 
node. The FNA of the thyroid nodule can then be evaluated according to the pathologic 
Bethesda System for Reporting Thyroid Cytopathology (22). Six different Bethesda 
diagnostic categories determine the follow-up measures, which range from clinical 
follow-up to surgical intervention (19, 22). When FNA indicates a strong possibility 
of malignant cells, treatment in children generally consists of a total thyroidectomy. 
Depending on the presence and the site of metastases, a central or (bi)lateral lymph 
node dissection can be performed (19). Children are postoperatively staged by means 
of the tumor-node-metastasis (TNM) classification (23, 24) and corresponding risk 
level of the disease (19), which determine the consecutive (intensity of the) treatment. 
After surgery, radioactive iodine (131I) can be administered. When administered in a high 
dose, the beta radiation of this radioisotope of iodine destroys thyroid cells (25), and 
may decrease the risk of recurrence of the disease (17, 26, 27). Although the precise role 
of 131I during treatment of low risk DTC has not yet been defined, the additional value 
of its administration in children with advanced disease is more established (27, 28). 
Subsequently, thyroid hormone supplementation with levothyroxine compensates 
the lack of thyroid hormone resulting from the thyroidectomy, but is also used to 
induce a certain level of TSH suppression (TSH suppression therapy). The aim of TSH 
suppression therapy is to suppress the growth-promoting effect of TSH on the thyroid 
cells, thereby preventing the (re)growth of malignant cells (29, 30). In high risk 
patients, a more intensive TSH suppression is advised. Recommendations are based 
on findings in adults, since no studies have as yet focused solely on evaluating children 
(19). Follow-up of the disease consists of clinical evaluation and neck palpation, US, 
and measuring of Tg during the thyroid hormone suppletion. Tg serves as a marker for 
residual or recurrent disease (19). 
Outcome after treatment of childhood differentiated thyroid cancer
Subsequent to treatment, survival rates of childhood DTC are up to 99% after 30 
years of follow-up (6, 31). Although survival in children is excellent, a relatively high 
percentage (10 to 30%) of the children develops recurrent disease, occurring even 




evidence of disease, which is called persistent disease. Recurrent or persistent disease 
occurs more frequently in patients with advanced disease upon diagnosis (35, 36). 
Differentiated thyroid cancer in children and adults
In the past, DTC was presumed to be similar in children and adults. However, more 
advanced knowledge indicates great differences between DTC in children and adults. 
Upon diagnosis, children present with more advanced and aggressive disease 
than do adults. Paradoxically, children have better overall survival rates in children 
than adults, but also more frequent persistent disease and recurrences (16-18, 31, 
32, 34, 37-43). In childhood, the mutational landscape of DTC differs from that of 
adults (44-54). Table 1 presents an overview an overview of differences between DTC 
diagnosed during childhood and adulthood. 
To date, however, no clear explanation can account for these differences between 
adult and childhood DTC. Although genetic alterations may play a role, studies are 
not conclusive. A higher expression of the sodium iodine symporter (NIS, essential in 
the uptake of iodine) in children may also help to explain their better responsiveness 
to 131I administrations, but ultimately the origin of the difference between adult and 
childhood DTC is probably multifactorial.
Adverse effects after childhood cancer 
Unfortunately, survivors of (childhood) cancer experience unwanted effects of 
the (treatment of the) cancer. These side effects are being increasingly recognized, as 
recent decades have seen an increase in the overall survival rate of childhood cancer 
(60). Side effects can occur during treatment, but may sometimes become manifest 
only years later. These late effects can be physical, mental, and/or psychosocial, such 
as cognitive impairment, fertility problems, diagnosis of a secondary malignancy, 
Table 1. Differences between DTC diagnosed during childhood and adulthood
Childhood DTC Adult DTC
Malignant origin of thyroid nodules (16, 18, 39, 40) 19 to 26% 12 to 14%
Incidence of lymph node metastases (17, 31, 34, 41-43, 55) 40 to 90% 15 to 50%
Incidence of distant metastases (17, 56, 57) 20 to 30% 2 to 20%
Most prevalent mutational alteration (44-54) RET fusion BRAF V600E mutation
Recurrence rate (32, 34, 58) Up to 32% 5%
Rate of persistent disease (32, 36, 58, 59) 5 to 33% 2 to 3%
10-year survival rate (17, 32, 37, 38) 95 to 100% 85 to 91% 
Abbreviations: DTC, differentiated thyroid carcinoma; RET, rearranged during transfection; BRAF, v-raf murine sarcoma 




and fatigue (61). Depending on the type of late effect, treatment or support can be 
offered, but not all effects can be prevented or resolved.
Adverse and late effects after childhood differentiated thyroid cancer
Because the majority of childhood DTC patients will survive their disease, it is important 
to evaluate late effects in these survivors. However, in contrast to the knowledge 
of late effects in many other childhood malignancies, little is known about possible 
adverse effects of childhood DTC. 
During treatment of DTC, surgical complications like surgical site infection, 
parathyroid damage (causing hypocalcaemia) and recurrent laryngeal nerve injury 
(causing hoarseness or loss of voice) can occur (62, 63). In addition, short-term side 
effects of 131I administration are radiation thyroiditis, nausea, vomiting, sialadenitis, 
gastro-intestinal symptoms, and bone-marrow suppression. In the long-term, 
administration of 131I for adult DTC is associated with salivary dysfunction or sialadenitis, 
pulmonary fibrosis, secondary malignancies, and gonadal damage in both men and 
women (causing fertility problems) (32, 64-69). Other long-term effects possibly 
induced by TSH suppression therapy are cardiovascular deterioration and loss of bone 
mineral density (also influenced by hypoparathyroidism) (29, 70-74). Moreover, general 
well-being or quality of life (QoL) can be affected by the diagnosis and the treatment 
of DTC (75-78). 
Some studies have been performed in survivors of childhood DTC, but current 
knowledge is based mainly on late effects of DTC on adults. Because of the differences 
between childhood and adult DTC, as shown above, late effects may also differ. 
However, specific knowledge of the late effects of treatment for DTC during childhood 
is limited because of the scarcity of studies, the small number of patients evaluated, 
the lack of clear study definitions, or the poor quality of study designs.
Aims and outline of this thesis
The aim of the current thesis is to evaluate the clinical course and late effects of 
childhood DTC. The results will ultimately benefit newly diagnosed patients, patients 
previously treated for DTC, caregivers, and treating physicians. 
A multicenter, cross-sectional study was conducted in the Netherlands. Patients 
diagnosed with DTC before the age of 19 years between 1970 and 2013 were included. 
Chapter 2 consists of an overview of the disease, treatment, outcomes, and follow-up 
characteristics of these patients. A minority of patients had distant metastases (DM). 
Chapter 3 specifically evaluates the clinical course of DTC in a large cohort of childhood 
DTC patients diagnosed with DM. This study was performed at the University of Texas 
MD Anderson Cancer Center in the United States. 
Long-term treatment effects of 131I after childhood DTC in the Netherlands are 




Chapter 4, where we evaluate reproductive characteristics in female survivors of 
childhood DTC, combined with levels of Anti-Müllerian hormone (AMH, a marker of 
ovarian reserve). Because the minority of childhood DTC patients is male, to attain 
a substantial and representative group of survivors, Chapter 5 includes a study of 
male fertility after treatment in survivors of adult DTC. Male fertility was evaluated by 
performing semen analyses, and assessing reproductive hormones and reproductive 
characteristics. Adverse effects of long-term TSH suppression therapy are evaluated 
in Chapter 6, including effects on cardiac function in survivors of childhood DTC. 
The first evaluation of these patients, performed five years after their childhood DTC 
diagnosis, showed that 21% of the survivors had asymptomatic diastolic dysfunction 
(79). Chapter 6 includes a re-evaluated of patients after a total follow-up period 
of 10 years to assess the course of their cardiac function. In Chapter 7, long-term 
thyroid cancer-specific QoL, health-related QoL, fatigue, and anxiety and depression 
are evaluated in survivors who were at least 5 years in follow-up after diagnosis. 
Because childhood cancer has been known to disrupt the course of life, Chapter 8 
evaluates psychosocial developmental milestones in childhood DTC survivors. 
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